Loading…
Loading…
Elekta AB (publ) (EKTAY) Q1 2027 Earnings Call Transcript
Elekta AB (publ) (EKTAY) Analyst/Investor Day Transcript
Elekta AB (publ) (EKTAY) Q4 2026 Earnings Call Transcript
Elekta AB (publ) is rated Buy with a 56 SEK ($6 ADR) price target, reflecting a 15% annualized return potential at 15x P/E. EKTAY's historical premium is no longer justified due to persistent earnings misses, slow growth, and margin challenges, but current valuation now offers upside. Recent improvements include a 300 bps EBIT margin rise, 4.3% yield with a 79% payout ratio, and positive book-to-bill and cash flow trends.
Elekta AB (publ) (EKTAY) Q3 2026 Earnings Call Transcript
Anteris Technologies Global (NASDAQ: AVR - Get Free Report) and Elekta (OTCMKTS:EKTAY - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership. Volatility and Risk Anteris Technologies Global has a
Elekta AB (publ) (EKTAY) Shareholder/Analyst Call Transcript
EKTAY jumps after FDA clears Evo CT-Linac, opening U.S. access to AI-driven CT imaging that boosts precision and efficiency in radiation therapy.
No recent filings indexed.